Q3-2019 Outsourced Pharma Services Update– As the number of independent CRO’s with market share continues to decrease, motivated strategic acquirers are investing in ancillary service lines such as clinical trial management via acquisitions of new sites.
“Provident listened to our story, confirmed that our business was valuable and made us feel like this was the only transaction important to them.”
“A lot of investment bankers were interviewed, Provident was chosen. Provident delivered. My clients could not be happier.”
”I have a tremendous amount of appreciation and gratitude to the Provident team for their hard work and diligence throughout this process. Each and every member of the Provident team is excellent at their jobs and it has been a pleasure working with such a professional team. Provident has provided outstanding guidance and counsel, and this deal could never have gotten done without Provident’s leadership.”
“We would not have been successful navigating the process without Provident’s hard work and active participation. They exceeded our expectations and we would highly recommend them to any health care company seeking a knowledgeable and engaged investment banking firm.”
“After working with Provident on several transactions, it is evident that their extensive industry knowledge and deal expertise prove to be invaluable to their clients.”
“Provident’s depth of experience and practical business savvy was demonstrated in their ability to cut through what sometimes looked like impasse.”
“While the decision to sell our business was a difficult one, Provident vigilantly represented and protected our best interests throughout the transaction. Provident was the right choice for Cascade and I would recommend their services to anyone.”